Barclays Raises Price Target for Becton Dickinson Following Strong Q2 Performance
Becton Dickinson reported solid fiscal Q2 results with revenue rising to $4.7 billion, driven by growth in biologic drug delivery and other segments. Barclays raised its price target on the stock from $202 to $204 while maintaining an Overweight rating.
Tickers: $BDX